

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **DISCLOSEABLE TRANSACTIONS REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS**

Reference is made to the announcement of the Company dated September 27, 2024 with respect to the subscription of a wealth management product in the amount of HK\$200,000,000 from Haitong ASM (the “**Haitong Product**”).

### **REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS**

The Board announces that the Company has given notice to Haitong ASM to redeem HK\$200,000,000 of the Haitong Product on June 16, 2025 in cash, representing its entire holding of the Haitong Product at the time, with an estimated gain of approximately HK\$5,102,000 (the “**Redemption**”), being unaudited interest income arising from the Redemption. After the Redemption, the Group will cease to hold any outstanding wealth management product from Haitong ASM. In addition, on June 16, 2025, the Company agreed to subscribe for a wealth management product (the “**Subscription**”) in the amount of HK\$205,000,000 from Shenwan Hongyuan Securities (H.K.) (the “**Shenwan Product**”). The Subscription was funded by the Group's internal surplus cash reserve.

### **IMPLICATIONS UNDER THE LISTING RULES**

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Redemption exceed 5% but are lower than 25%, the Redemption constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription exceed 5% but are lower than 25%, the Subscription constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

## **REDEMPTION OF THE WEALTH MANAGEMENT PRODUCT**

On September 27, 2024, the Company subscribed for the Haitong Product in the amount of HK\$200,000,000 from Haitong ASM, using its internal surplus cash reserves, pursuant to terms of which, the Haitong Product is redeemable upon giving notice seven business days in advance by the Company.

On June 16, 2025, the Company has given notice to Haitong ASM to redeem HK\$200,000,000 of the Haitong Product in cash, representing its entire holding of the Haitong Product at the time, with an estimated gain of approximately HK\$5,102,000, being unaudited interest income arising from the Redemption. The proceeds from the Redemption will be used as general working capital and short-term cash management investments (if applicable) of the Group. The actual amount of gain or loss arising from the Redemptions is subject to audit and/or review by the auditors of the Company. After the Redemption, the Group will cease to hold any outstanding wealth management product from Haitong ASM.

## **REASONS FOR AND BENEFITS OF THE REDEMPTION**

The Group subscribed for the Haitong Product, using its internal surplus cash reserves, with an aim to making full use of its idle funds and improving the rate of return on idle funds. In view of the recent internal adjustments to the organizational structure of Guotai Haitong Group (as defined below) and the Company's treasury policy, the Group carried out the Redemption. The Redemption of Haitong Product will help to enhance overall returns and flexibility of the Group's idle funds. The Directors believe that the Redemption is on normal commercial terms, fair and reasonable, in line with the treasury policy of the Company and in the interests of the Company and the Shareholders as a whole.

## THE SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

On June 16, 2025, the Company agreed to subscribe for the Shenwan Product in the amount of HK\$205,000,000 from Shenwan Hongyuan Securities (H.K.). The Group utilised its internal surplus cash reserves for the payment of the subscription amount. The major terms and conditions of the Subscription are summarised below:

- |  |   |
|--|---|
| (1) Expected effective date of the Subscription: | June 24, 2025   |
| (2) Name of the product:                         | Notes linked to cash management funds   |
| (3) Parties:                                     | (i) Shenwan Hongyuan Financial Products, as the issuer;<br>(ii) Shenwan Hongyuan Securities (H.K.), as the dealer; and<br>(iii) the Company, as the subscriber                |
| (4) Type of the product:                         | Structured note   |
| (5) Principal amount subscribed:                 | HK\$205,000,000   |
| (6) Term of investment:                          | one year, redeemable upon giving notice ten business days in advance by the Company   |
| (7) Expected annualized rate of return:          | expected to be 3.0%–4.0%, subject to the actual return rate of the underlying assets  |
| (8) Investment scope of the product:             | underlying subject of cash management products, e.g., cash, bank deposits, bank certificates, short term U.S. treasury bonds, or other cash management investment instruments |

## BASIS OF DETERMINATION FOR THE CONSIDERATION

The Directors confirmed that the consideration for the Subscription was determined on the basis of commercial terms negotiated at arm's length among the Company, Shenwan Hongyuan Securities (H.K.) and Shenwan Hongyuan Financial Products, having considered the surplus cash reserves of the Group available for treasury management purpose.

## **REASONS FOR AND BENEFITS OF THE SUBSCRIPTION**

The Directors are of the view that (i) appropriate wealth management with low risk exposure is conducive to enhancing the utilisation of capital and increasing income from idle funds of the Group; (ii) diversified, readily redeemable investments in cash management products are conducive to enhancing the safety and flexibility of cash management; and (iii) the Subscription was funded by the Group's internal surplus cash reserves, and thus would not affect the Group's working capital position or operation. Accordingly, the Directors consider that the terms of the Subscription are fair and reasonable, on normal commercial terms, and in the interests of the Company and the Shareholders as a whole.

## **INFORMATION ON THE PARTIES**

### **The Company**

The Company is a joint stock company incorporated in the PRC with limited liability on June 14, 2022. The Company is a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies.

### **Shenwan Hongyuan Securities (H.K.)**

Shenwan Hongyuan Securities (H.K.) is a company incorporated in Hong Kong with limited liability on May 28, 1974 and a wholly-owned subsidiary of Shenwan Hongyuan (H.K.) Limited (申萬宏源(香港)有限公司), a company incorporated in Hong Kong with limited liability and listed on the Stock Exchange (stock code: 218), the ultimate holding company of which in turn is Shenwan Hongyuan Group Co., Ltd. (申萬宏源集團股份有限公司), a joint stock company incorporated in the PRC and dually listed on Shenzhen Stock Exchange (stock code: 000166) and the Stock Exchange (stock code: 6806). Shenwan Hongyuan Securities (H.K.) is principally engaged in provision of securities brokerage.

### **Shenwan Hongyuan Financial Products**

Shenwan Hongyuan Financial Products (a wholly-owned subsidiary of Shenwan Hongyuan (H.K.) Limited) is a company incorporated in the British Virgin Islands with limited liability, and is principally engaged in provision of financing services.

As of the date of this announcement and to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Shenwan Hongyuan Securities (H.K.), Shenwan Hongyuan Financial Products and their ultimate beneficial owner are third parties independent of each of the Company and its connected persons (as defined under the Listing Rules).

## Haitong ASM

Haitong ASM is a direct wholly-owned subsidiary of Haitong International Securities Group Limited (海通國際證券集團有限公司) (“**Haitong International**”). Haitong International is a wholly-owned subsidiary of Haitong International Holdings Limited, which is a direct wholly-owned subsidiary of Guotai Haitong Securities Co., Ltd. (國泰海通證券股份有限公司) (stock code: 601211.SH, 2611.HK) (“**Guotai Haitong Group**”). Haitong ASM is licensed with the Securities and Futures Commission of Hong Kong to carry on Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 9 (asset management) regulated activities as stipulated in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Haitong ASM is principally engaged in provision of investment management services on diversified and comprehensive investment products including actively and passively managed funds to individual, corporate and institutional investors.

As of the date of this announcement and to the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, Haitong ASM and its ultimate beneficial owner are third parties independent of each of the Company and its connected persons (as defined under the Listing Rules).

## IMPLICATIONS UNDER THE LISTING RULES

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Redemption exceed 5% but are lower than 25%, the Redemption constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders’ approval requirement under Chapter 14 of the Listing Rules.

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription exceed 5% but are lower than 25%, the Subscription constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders’ approval requirement under Chapter 14 of the Listing Rules.

## DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“Board”	the board of Directors
“Company”	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (宜明昂科生物醫藥技術(上海)股份有限公司), a joint stock company incorporated in the People’s Republic of China with limited liability on June 14, 2022, the H shares of which are listed on the Stock Exchange (stock code: 1541), or, where the context requires (as the case may be), its predecessor, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (宜明昂科生物醫藥技術(上海)有限公司), a limited liability company established in the PRC on June 18, 2015
“connected person(s)”	has (have) the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Haitong ASM”	Haitong International Asset Management (Hong Kong) Limited (海通國際資產管理(香港)有限公司), a company incorporated in Hong Kong with limited liability
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)
“percentage ratios”	have the same meaning as ascribed to it under the Listing Rules
“PRC”	the People’s Republic of China, and except where the context otherwise requires, references in this announcement to the PRC or Mainland China exclude Hong Kong, China, Macau, China and Taiwan, China

“Shareholder(s)”	holder(s) of the shares of the Company
“Shenwan Hongyuan Financial Products”	Shenwan Hongyuan Financial Products Company Limited, a company incorporated in the British Virgin Islands with limited liability
“Shenwan Hongyuan Securities (H.K.)”	Shenwan Hongyuan Securities (H.K.) Limited (申萬宏源證券(香港)有限公司), a company incorporated in Hong Kong with limited liability
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“%”	per cent

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
 宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, June 16, 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*